mRNA Vaccine and Therapeutics Market Size, Share, Growth & Industry Analysis, By Product Type (mRNA Vaccines, mRNA Therapeutics (Oncology, Infectious Diseases, Rare Diseases)) By Application (Infectious Disease Prevention, Cancer Immunotherapy, Protein Replacement, Others) By End User (Hospitals, Clinics, Research Institutes, Biopharmaceutical Companies), and Regional Analysis, 2024-2031

1 INTRODUCTION OF THE GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET
1.1 MARKET Definition
1.2 MARKET Segmentation
1.3 Research Timelines
1.4 Limitations
1.5 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Collection
3.1.1 Secondary Sources
3.1.2 Primary Sources
3.1.3 Research Flow
3.2 Subject Matter Expert Advice
3.3 Quality Check
3.4 Final Review
3.5 Bottom-Up Approach
3.6 Top-down Approach

4 GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET OUTLOOK
4.1 MARKET Evolution
4.2 Overview
4.3 MARKET Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.3.4 Challenges
4.4 Pricing Analysis
4.5 Porter’s Five Forces Analysis
4.6 Value Chain Analysis
4.7 Macroeconomic Analysis

5 IMPACT OF RUSSIA-UKRAINE WAR

6 GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET, BY PRODUCT TYPE
6.1 Overview
6.2 mRNA Vaccines
6.3 mRNA Therapeutics (Oncology, Infectious Diseases, Rare Diseases)

7 GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION
7.1 Overview
7.2 Infectious Disease Prevention
7.3 Cancer Immunotherapy
7.4 Protein Replacement
7.5 Others

8 GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET, BY END USER
8.1 Overview
8.2 Hospitals
8.3 Clinics, Research Institutes
8.4 Biopharmaceutical Companies

9 GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET, BY GEOGRAPHY
9.1 Overview

10 NORTH AMERICA
10.1 U.S.
10.2 Canada
10.3 Mexico

11 EUROPE
11.1 Germany
11.2 UK
11.3 France
11.4 Italy
11.5 Spain
11.6 Russia
11.7 Rest of Europe

12 ASIA-PACIFIC
12.1 China
12.2 Japan
12.3 India
12.4 South Korea
12.5 Rest of Asia-Pacific

13 MIDDLE EAST & AFRICA
13.1 GCC
13.2 South Africa
13.3 North Africa
13.4 Rest of Middle East & Africa

14 LATIN AMERICA
14.1 Brazil
14.2 Argentina
14.3 Rest of South America

15 GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
15.1 Overview
15.2 Key Developments
15.3 Key Strategic Developments
15.4 Company MARKET Ranking
15.5 Regional Footprint
15.6 Industry Footprint

16 COMPANY PROFILES
16.1 Moderna, Inc.
16.1.1 Key Facts
16.1.2 Financial Overview
16.1.3 Product Benchmarking
16.1.4 Recent Developments
16.1.5 Winning Imperatives
16.1.6 Current Focus & Strategies
16.1.7 Threat from competition
16.1.8 SWOT Analysis
16.2 BioNTech SE
16.2.1 Key Facts
16.2.2 Financial Overview
16.2.3 Product Benchmarking
16.2.4 Recent Developments
16.2.5 Winning Imperatives
16.2.6 Current Focus & Strategies
16.2.7 Threat from competition
16.2.8 SWOT Analysis
16.3 CureVac AG
16.3.1 Key Facts
16.3.2 Financial Overview
16.3.3 Product Benchmarking
16.3.4 Recent Developments
16.3.5 Winning Imperatives
16.3.6 Current Focus & Strategies
16.3.7 Threat from competition
16.3.8 SWOT Analysis
16.4 Pfizer Inc.
16.4.1 Key Facts
16.4.2 Financial Overview
16.4.3 Product Benchmarking
16.4.4 Recent Developments
16.4.5 Winning Imperatives
16.4.6 Current Focus & Strategies
16.4.7 Threat from competition
16.4.8 SWOT Analysis
16.5 Translate Bio (now part of Sanofi)
16.5.1 Key Facts
16.5.2 Financial Overview
16.5.3 Product Benchmarking
16.5.4 Recent Developments
16.5.5 Winning Imperatives
16.5.6 Current Focus & Strategies
16.5.7 Threat from competition
16.5.8 SWOT Analysis
16.6 Arcturus Therapeutics
16.6.1 Key Facts
16.6.2 Financial Overview
16.6.3 Product Benchmarking
16.6.4 Recent Developments
16.7 GSK plc
16.7.1 Key Facts
16.7.2 Financial Overview
16.7.3 Product Benchmarking
16.7.4 Recent Developments
16.8 Sanofi S.A.
16.8.1 Key Facts
16.8.2 Financial Overview
16.8.3 Product Benchmarking
16.8.4 Recent Developments
16.9 Novartis AG
16.9.1 Key Facts
16.9.2 Financial Overview
16.9.3 Product Benchmarking
16.9.4 Recent Developments
16.10 Johnson & Johnson
16.10.1 Key Facts
16.10.2 Financial Overview
16.10.3 Product Benchmarking
16.10.4 Recent Developments

LIST OF TABLES

TABLE 1 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 2 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 3 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 4 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue, By Geography, 2021 – 2031 (USD Billion)
TABLE 5 North America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 6 North America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 7 North America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 8 North America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 9 US mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 10 US mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 11 US mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 12 Canada mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 13 Canada mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 14 Canada mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 15 Mexico mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 16 Mexico mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 17 Mexico mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 18 Europe mRNA VACCINE AND THERAPEUTICS MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 19 Europe mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 20 Europe mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 21 Europe mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 22 Germany mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 23 Germany mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 24 Germany mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 25 France mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 26 France mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 27 France mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 28 UK mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 29 UK mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 30 UK mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 31 Spain mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 32 Spain mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 33 Spain mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 34 Italy mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 35 Italy mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 36 Italy mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 37 Russia mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 38 Russia mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 39 Russia mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 40 Rest of Europe mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 41 Rest of Europe mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 42 Rest of Europe mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 43 Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 44 Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 45 Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 46 Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 47 China mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 48 China mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 49 China mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 50 Japan mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 51 Japan mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 52 Japan mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 53 India mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 54 India mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 55 India mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 56 South Korea mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 57 South Korea mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 58 South Korea mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 59 Rest of Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 60 Rest of Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 61 Rest of Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 62 Middle East and Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 63 Middle East and Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 64 Middle East and Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 65 Middle East and Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 66 GCC mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 67 GCC mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 68 GCC mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 69 North Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 70 North Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 71 North Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 72 South Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 73 South Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 74 South Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 75 Rest of Middle East & Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 76 Rest of Middle East & Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 77 Rest of Middle East & Africa mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 78 Latin America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 79 Latin America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 80 Latin America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 81 Latin America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 82 Brazil mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 83 Brazil mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 84 Brazil mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 85 Argentina mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 86 Argentina mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 87 Argentina mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 88 Rest of Latin America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY PRODUCT TYPE, 2021 – 2031 (USD Billion)
TABLE 89 Rest of Latin America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY APPLICATION, 2021 – 2031 (USD Billion)
TABLE 90 Rest of Latin America mRNA VACCINE AND THERAPEUTICS MARKET Revenue, BY END USER, 2021 – 2031 (USD Billion)
TABLE 91 Company MARKET Ranking
TABLE 92 Regional Footprint
TABLE 93 Product Benchmarking
TABLE 94 Recent Developments
TABLE 95 Winning Imperatives

LIST OF FIGURES

FIG. 1 MARKET Segmentation
FIG. 2 Research Timeline
FIG. 3 Global mRNA VACCINE AND THERAPEUTICS MARKET 2021-2031 (USD Billion)
FIG. 4 Global mRNA VACCINE AND THERAPEUTICS MARKET Geographical Analysis (CAGR %)
FIG. 5 Global mRNA VACCINE AND THERAPEUTICS Absolute MARKET Opportunity (USD Billion)
FIG. 6 Global mRNA VACCINE AND THERAPEUTICS MARKET Attractiveness (USD Billion)
FIG. 7 Global mRNA VACCINE AND THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2031 (USD Billion)
FIG. 8 Global mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION, 2021-2031 (USD Billion)
FIG. 9 Global mRNA VACCINE AND THERAPEUTICS MARKET, BY END USER, 2021-2031 (USD Billion)
FIG. 10 Research Methodology
FIG. 11 Research Process
FIG. 12 Bottom-Up Approach
FIG. 13 Top-Bottom Approach
FIG. 14 MARKET Dynamics Overview
FIG. 15 Porter's Five Forces Analysis
FIG. 16 Value Chain Analysis
FIG. 17 Macroeconomic Analysis
FIG. 18 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue Share, BY PRODUCT TYPE, 2021 and 2031 (%)
FIG. 19 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue Share, BY APPLICATION, 2021 and 2031 (%)
FIG. 20 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue Share, BY END USER, 2021 and 2031 (%)
FIG. 21 Global mRNA VACCINE AND THERAPEUTICS MARKET Revenue Share, By Geographic Regions, 2021 and 2031 (%)
FIG. 22 MARKET Size and Projections, 2021 - 2031 (USD Billion)
FIG. 23 North America mRNA VACCINE AND THERAPEUTICS MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 24 MARKET Size and Projections, 2021 - 2031 (USD Billion)
FIG. 25 Europe mRNA VACCINE AND THERAPEUTICS MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 26 MARKET Size and Projections, 2021 - 2031 (USD Billion)
FIG. 27 Asia-Pacific mRNA VACCINE AND THERAPEUTICS MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 28 MARKET Size and Projections, 2021 - 2031 (USD Billion)
FIG. 29 Middle East & Africa mRNA VACCINE AND THERAPEUTICS MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 30 MARKET Size and Projections, 2021 - 2031 (USD Billion)
FIG. 31 Latin America mRNA VACCINE AND THERAPEUTICS MARKET Overview Share, By Countries, 2021 – 2031 (%)
FIG. 32 Key Strategic Development
FIG. 33 Key Facts
FIG. 34 Financial Overview
FIG. 35 SWOT Analysis